PracticeConsultingNewswatch: Drugs firm set to float.

Newswatch: Drugs firm set to float.

Former PricewaterhouseCoopers corporate finance expert Dr Neil Johnston has had to hit the ground running in his first two months as group financial officer at Pharmagene, the biotechnology group which tests drugs on human tissues, writes Jerry Frank.

Dr Johnston has brought his experience at PwC in private placements and public listings to bear as Pharmagene prepared for a London Stock Exchange listing due this Monday.

An associate member of the Society of Actuaries with a PhD in molecular biology, 33-year-old Johnston can stand his own scientifically and financially in a highly-qualified boardroom.

Pharmagene now has one of the world’s most extensive collections of human tissue for the pharmaceutical industry to carry out pre-clinical testing on drugs during development, which reduces the risk of subsequent failure in the clinic.

Doctors Gordon Baxter and Robert Coleman founded the company in 1996 with equity funding worth #1.4m, with a further #5m raised the following year.

The Hertfordshire-based company has been valued at #140m with share prices between 240p and 320p, and is due to raise #40m to fund sales and marketing restructuring, and open a United States office.

Former GP and chief executive Dr Alastair Riddell said: ‘The recent sequencing of the human genome provides a significant opportunity for Pharmagene, in that we can help take this sequence information to the next level – that is gene function.’

Johnston replaced William Buckie as FD, a Cambridge biochemistry PhD and Coopers & Lybrand trained accountant, who has taken over as company secretary.

www.pharmagene.com.

Related Articles

5 tips for SMEs to protect cash flow

Accounting Software 5 tips for SMEs to protect cash flow

5m Alia Shoaib, Reporter
Tyrie on Finance Bill 2017: ‘Making Tax Policy Better’

Consulting Tyrie on Finance Bill 2017: ‘Making Tax Policy Better’

11m Stephanie Wix, Writer
Managing partner Q&A - the year ahead: Richard Toone, CVR Global

Accounting Firms Managing partner Q&A - the year ahead: Richard Toone, CVR Global

12m Kevin Reed, Writer
Deloitte 'self-imposes exile' on government contracts to defuse PM row

Accounting Firms Deloitte 'self-imposes exile' on government contracts to defuse PM row

12m Kevin Reed, Writer
Managing partner Q&A - the year ahead: Julie Adams, Menzies

Accounting Firms Managing partner Q&A - the year ahead: Julie Adams, Menzies

12m Kevin Reed, Writer
Friday Afternoon Live: Deloitte's tech thing; PAC wants HMRC 'contingencies'; and Sports Direct

Business Regulation Friday Afternoon Live: Deloitte's tech thing; PAC wants HMRC 'contingencies'; and Sports Direct

1y Kevin Reed, Writer
Friday Afternoon Live: HMRC complaints rise; Deloitte scoops big audits; and corporate reporting woes

Audit Friday Afternoon Live: HMRC complaints rise; Deloitte scoops big audits; and corporate reporting woes

1y Kevin Reed, Writer
New head of equity capital markets for KPMG

Accounting Firms New head of equity capital markets for KPMG

1y Stephanie Wix, Writer